Norway: problems which a small and sparsely populated European country without a national vaccine production would face during a pandemic.
Since Norway at present has no national influenza vaccine production, there is some concern that during a pandemic influenza situation it would be difficult to secure even a limited quantity of appropriate influenza vaccine. It is conceivable that national emergency directives declared in the manufacturing countries would ban or severely hinder export of a life-saving commodity such as influenza vaccine. Most probably, this would be the situation for all European countries without a national influenza vaccine production. To ensure vaccine availability for the purchasing country even under a national influenza emergency situation declared in the manufacturing country such agreements must be safe against unilateral cancellation.
Department of Microbiology and Immunology, University of Bergen, Norway.
L R
LR
Haaheim
D000368:Aged; D004196:Disease Outbreaks / Q000517:prevention & control; D004345:Drug Industry / Q000331:legislation & jurisprudence; D004630:Emergencies; D005060:Europe / Q000453:epidemiology; D006291:Health Policy; D006801:Humans; D007252:Influenza Vaccines / Q000138:chemical synthesis / Q000600:supply & distribution*; D007251:Influenza, Human / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D007391:International Cooperation; D009664:Norway / Q000453:epidemiology; D011159:Population Surveillance; D014611:Vaccination
D007252:Influenza Vaccines